ASTELLAS PHARMA UNSP.ADR (YPHA) — Working Capital to Net Assets Ratio
ASTELLAS PHARMA UNSP.ADR (YPHA) has a Working Capital to Net Assets ratio of 9.2% as of March 2025. Working capital of €139.74 Billion (current assets of €1.20 Trillion minus current liabilities of €1.06 Trillion) is measured against net assets of €1.51 Trillion. A higher ratio indicates strong short-term liquidity financed by the equity base. See ASTELLAS PHARMA UNSP.ADR balance sheet quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ASTELLAS PHARMA UNSP.ADR Working Capital to Net Assets (2022–2025)
This chart shows how ASTELLAS PHARMA UNSP.ADR's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2022 to 2025. As of March 2025, the ratio stands at 9.2%, reflecting working capital of €139.74 Billion against net assets of €1.51 Trillion EUR. Check YPHA tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for ASTELLAS PHARMA UNSP.ADR (2022–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for ASTELLAS PHARMA UNSP.ADR from 2022 to 2025, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see ASTELLAS PHARMA UNSP.ADR stock valuation.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 9.2% | €139.74 Billion | €1.51 Trillion | €1.20 Trillion | €1.06 Trillion | ▲ +14.9 pp |
| 2024 | -5.7% | €-91.00 Billion | €1.60 Trillion | €1.19 Trillion | €1.29 Trillion | ▼ -27.2 pp |
| 2023 | 21.5% | €323.92 Billion | €1.51 Trillion | €1.05 Trillion | €726.03 Billion | ▲ +5.3 pp |
| 2022 | 16.2% | €235.94 Billion | €1.46 Trillion | €923.35 Billion | €687.41 Billion | — |